Search Results - george+lountos

2 Results

Sort By:

Sensitizing Cancer Cells to DNA Targeted Therapies

Abstract: Chk2 is a protein kinase activated in response to DNA double strand breaks. In normal tissues, Chk2 phosphorylates and thereby activates substrates that induce programmed cell death, or apoptosis, via interactions with p53, E2F1, PML proteins. In cancer tissues, where apoptosis is suppressed, Chk2 phosphorylates and inactivates cell cycle...

Published: 4/8/2024 | Inventor(s): Yves Pommier, Dominic Scudiero, Christopher Self, Robert Shoemaker, David Waugh, Guangtao (George) Zhang, John Cardellina, Michael Currens, Andrew Collasanti, Charles Cook, Andrew Jobson, Sudhir Kondapaka, George Lountos

Keywords(s): Anti-cancer Therapeutic, Chk2 Inhibitors, Sensitizing Agent for current DNA-damaging cancer therapeuti

Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics

Novel Small Molecule Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treatment of Solid Tumors

Abstract: Topoisomerase 1 (TOP1) is an essential enzyme that plays a critical role in DNA transcription and replication. TOP1 inhibitors are a known class of anti-cancer agents that work to interrupt DNA replication in cancer cells, causing cell death. Since the discovery of the TOP1 inhibitor camptothecin (CPT) from plant extracts more than 60 years...

Published: 5/22/2024 | Inventor(s): Xue Zhao, George Lountos, Evgeny Kiselev, David Waugh, Yves Pommier, Terrence Burke

Keywords(s): Burke, CANCER, solid tumor, Tdp1, TOP1, Topoisomerase 1, Tyrosyl-DNA Phosphodiesterase 1, Zhao

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology